Cellular uptake of two fluoroketolides, HMR 3562 and HMR 3787, by human polymorphonuclear neutrophils in vitro.
We analyzed the cellular accumulation of two new fluoroketolides, HMR 3562 and HMR 3787, by human polymorphonuclear neutrophils (PMN) in vitro. Both compounds were rapidly taken up by PMN, with a cellular-to-extracellular concentration ratio (C/E) of about 141 (HMR 3562) and 117 (HMR 3787) at 5 min, and this was followed by a plateau at 60 to 180 min, with a C/E of >300 at 180 min. Both ketolides were mainly located in PMN granules (about 75%) and egressed slowly from loaded cells (about 40% at 60 min), owing to avid reuptake. Uptake was moderately sensitive to external pH, and activation energy was also moderate (about 70 kJ/mol). As with other macrolides and ketolides, the existence of an active transport system was suggested by (i) the strong interindividual variability in uptake kinetics, suggesting variability in the number or activity of a transport protein; (ii) the saturation kinetics characteristic of a carrier-mediated transport system (V(max), about 2,300 ng/2.5 x 10(6) PMN/5 min; K(m), about 50 microg/ml); (iii) the inhibitory effects of Ni(2+) (a blocker of the Na+-Ca(2+) exchanger), phorbol myristate acetate (a protein kinase C activator), and H89 (a protein kinase A inhibitor). Although these two ketolides are more related to HMR 3647 (telithromycin), it is interesting that the presence of a fluoride gave these molecules a cellular pharmacokinetics more like those of HMR 3004 than those of HMR 3647. The macrolide transport system has not been yet elucidated, but our data confirm that, despite variations in chemical structure, all erythromycin A derivatives share a transmembrane transport system.
Abdelghaffar
H
H
INSERM U479, CHU Xavier Bichat, 16 rue Henri Huchard, 75018 Paris, France.
Vazifeh
D
D
Labro
M T
MT
D019297:2,4-Dinitrophenol / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D001692:Biological Transport / Q000187:drug effects; D002470:Cell Survival / Q000502:physiology; D004347:Drug Interactions; D006801:Humans; D006863:Hydrogen-Ion Concentration; D018942:Macrolides; D009504:Neutrophils / Q000378:metabolism*; D012969:Sodium Fluoride / Q000494:pharmacology; D013347:Subcellular Fractions; D013696:Temperature; D014475:Uncoupling Agents / Q000494:pharmacology
D000900:Anti-Bacterial Agents; C438106:HMR 3562; C439346:HMR 3787; D018942:Macrolides; D014475:Uncoupling Agents; D012969:Sodium Fluoride; D019297:2,4-Dinitrophenol